Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer by unknown
Nodin et al. Diagnostic Pathology 2013, 8:106
http://www.diagnosticpathology.org/content/8/1/106RESEARCH Open AccessClinicopathological correlates and prognostic
significance of KRAS mutation status in a pooled
prospective cohort of epithelial ovarian cancer
Björn Nodin1*, Nooreldin Zendehrokh1, Magnus Sundström2 and Karin Jirström1Abstract
Background: Activating KRAS mutations are common in ovarian carcinomas of low histological grade, less
advanced clinical stage and mucinous histological subtype, and form part of the distinct molecular alterations
associated with type I tumors in the dualistic model of ovarian carcinogenesis. Here, we investigated the
occurrence, clinicopathological correlates and prognostic significance of specific KRAS mutations in tumours from
153 epithelial ovarian cancer (EOC) cases from a pooled, prospective cohort.
Methods: KRAS codon 12,13 and 61 mutations were analysed by pyrosequencing in tumours from 163 incident
EOC cases in the Malmö Diet and Cancer Study and Malmö Preventive Project. Associations of mutational status
with clinicopathological and molecular characteristics were assessed by Pearson Chi Square test. Ovarian
cancer-specific survival (OCSS) according to mutational status was explored by Kaplan-Meier analysis and Cox
proportional hazards modelling. KRAS-mutation status was also analysed in 28 concomitantly sampled
benign-appearing fallopian tubes.
Results: Seventeen (11.1%) EOC cases harboured mutations in the KRAS gene, all but one in codon 12, and one in
codon 13. No KRAS mutations were found in codon 61 and all examined fallopian tubes were KRAS wild-type. KRAS
mutation was significantly associated with lower grade (p = 0.001), mucinous histological subtype (p = < 0.001) and
progesterone receptor expression (p = 0.035). Kaplan-Meier analysis revealed a significantly improved OCSS for patients
with KRAS-mutated compared to KRAS wild-type tumours (p = 0.015). These associations were confirmed in unadjusted
Cox regression analysis (HR = 2.51; 95% CI 1.17-5.42) but did not remain significant after adjustment for age, grade and
clinical stage. The beneficial prognostic impact of KRAS mutation was ony evident in tumours of low-intermediate
differentiation grade (p = 0.023), and in a less advanced clinical stage (p = 0.014). Moreover, KRAS mutation was
associated with a significantly improved OCSS in the subgroup of endometroid carcinomas (p = 0.012).
Conclusions: The results from this study confirm previously demonstrated associations of KRAS mutations with
well-differentiated and mucinous ovarian carcinomas. Moreover, KRAS-mutated tumours had a significantly improved
survival in unadjusted, but not adjusted, analysis. A finding that merits further study is the significant prognostic impact
of KRAS mutation in endometroid carcinomas, potentially indicating that response to Ras/Raf/MEK/ERK-targeting
therapies may differ by histological subtype.
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Epithelial ovarian cancer (EOC) is the the leading cause
of death from gynaecological malignancies and the fifth
most common cause of cancer-related death in women
[1]. Etiological factors involved in ovarian carcinogenesis
remain poorly defined and the pitiable percentage of sur-
vival to incidence is related to cases being diagnosed in
an advanced stage, most often stage III and IV, i.e. hav-
ing metastatic spread to the lining of the abdomen or
distant sites. Most patients relapse within 3 to 5 years
despite harsh surgery and chemotherapy treatment [2].
Consequently, there is an urgent need to identify novel
diagnostic, prognostic, and predictive biomarkers for de-
velopment of improved personalized therapeutic regi-
mens for ovarian cancer patients.
The KRAS (v-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog) gene encodes the K-Ras protein, an im-
portant component of the tyrosine kinase signaling
RAS/MAPK pathway. The K-Ras protein functions as a
binary switch, binding GDP in its inactive state and GTP
in the active, signal-emitting, state. To inactivate itself,
the K-Ras protein interacts with GTPase-activating pro-
teins (GAPs) and, when bound to GDP, it is not able to
transmit signals to the cell nucleus. Missense point mu-
tations in the KRAS gene abolish the GTPase function
and, hence, lead to a constitutively activated protein that
cannot turn itself off [3,4]. KRAS mutations, most com-
monly affecting codons 12 and 13, have been described
in different types of solid tumors, with the highest pro-
portion (up to 90%) reported in pancreatic cancer [5,6].
In recent years, the 2-type system for classification of
EOC, proposed by Shih and Kurman in 2004, has be-
come generally accepted [7]. According to this system,
Type 2 cancers, encompassing the clinically more ag-
gressive high-grade serous carcinomas, are defined by
frequent mutations in p53 and BRCA1/2 genes, lead-
ing to genomic instability, while type 1 tumours,
encompassing low-grade serous and endometroid car-
cinomas, clear cell, mucinous and transitional cell
(Brenner) tumours, are characterized by common
KRAS mutations [8,9]. KRAS mutations seem to occur
early in the development of low-grade tumours, since
they can be found in benign and borderline areas
within the same neoplasm [10-14].
The aim of the present study was to examine the occur-
rence, clinicopathological correlates and prognostic signifi-
cance of KRAS mutation status in tumours from 154




The study cohort is a pooled cohort consisting of all in-
cident cases of EOC in the population-based prospectivecohort studies Malmö Diet and Cancer Study (n = 101)
[15] and Malmö Preventive Project Cohort (n = 108)
[16] until Dec 31st 2007. Thirty-five patients participated
in both studies, and archival tumor tissue could be re-
trieved from 154 (88,5%) of the total number of 174
cases. Cases were identified from the Swedish Cancer
Registry up until 31 Dec 2006, and from The Southern
Swedish Regional Tumour Registry for the period of 1
Jan - 31 Dec 2007. Histopathological, clinical and treat-
ment data were obtained from the clinical and/or path-
ology records. Tumors were also re-evaluated regarding
histological subtype and histological grade, using a
three-tiered system, by a board certified pathologist (KJ).
Information regarding clinical stage was obtained from
the medical charts, following the standardized FIGO
classification of tumor staging. Information on residual
tumor after surgery was not available. Standard adjuvant
therapy was platinum-based chemotherapy, from the
1990s given in combination with paclitaxel.
Information on vital status and cause of death was
obtained from the Swedish Cause of Death Registry up
until 31 Dec 2008. Follow-up started at date of diagnosis
and ended at death, emigration or 31 Dec 2008, which-
ever came first. After a median follow-up of 2.65 years
(range 0–21), 105 patients (68.2%) were dead and 49
(31.8%) alive. Patient-and tumour characteristics of the
cohort have been described in detail previously [17-19].
Ethical permissions for the MDCS (Ref. 51/90), and the
present study (Ref. 530/2008), were obtained from the
Ethics Committee at Lund University.
Tissue microarray construction and
immunohistochemistry
TMAs were constructed as previously described [20].
Two 1 mm cores were taken from viable, non-necrotic
tumor areas, when possible from both ovaries, and from
concomitant peritoneal metastases (n = 33). Fallopian
tubes with no evidence of histological disease were also
sampled from 38 cases. Immunohistochemical expres-
sion of androgen receptor (AR), estrogen receptor (ER),
progesterone receptor (PR), RNA-binding motif protein
3 (RBM3), minichromosome maintenance 3 protein
(MCM3), Chek1, Chek2, Ki67 and special AT-rich
sequence-binding protein1 (SATB1) was performed as
previously described [17,21,22].
Analysis of KRAS mutation status
The PyroMark Q24 system (Qiagen GmbH, Hilden,
Germany) was used for pyrosequencing analysis of
KRAS mutations on 1 mm formalin fixed paraffin-
embedded tissue cores from benign-appearing fallopian
tubes and from areas with >90% tumour cells in primary
tumours. In brief, genomic DNA was extracted from
tumour tissue in QIAamp MinElute spin columns
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PCR (Veriti 96 Well Fast Thermal Cykler, Applied
Biosystems Inc., Foster City CA). Using therascreen
KRAS Pyro Kit (Qiagen) KRAS mutations of codon 12,
13 and 61 were analysed and samples with a potential
low-level mutation were reexamined in duplicates.
Statistical analysis
Pearson’s Chi Square test was used for analysis of asso-
ciations between KRAS mutation status and clini-
pathological and tumour biological characteristics.
Kaplan-Meier analysis and log rank test were used to il-
lustrate differences in ovarian cancer specific survival
(OCSS) and overall survival (OS) according to KRAS
mutation status in the full cohort and in strata according
to differentiation grade, clinical stage and histological
subtype. Cox regression proportional hazards models
were used for estimation of hazard ratios (HRs) for
death from ovarian cancer or overall causes according to
KRAS mutation status in both uni- and multivariable
analysis, adjusted for age, stage and differentiation grade.
All calculations were performed using IBM SPSS Statis-
tics Version 20 (SPSS Inc, Chicago, IL). All statistical
tests were two-sided and a p value < 0.05 was considered
statistically significant.
Results
Frequency of KRAS mutations in primary tumours and
benign-appearing fallopian tubes
KRAS mutation status could be assessed in 153/154
(99.3%) tumours. In the studied cohort of 153 EOC
cases, 17 (11.1%) displayed mutations in the KRAS gene,
16 (10.5%) of which in codon 12 and 1 (0.7%) in codon
13. The most commonly found amino acid substitutions
in codon 12 were G12D (gly12→ asp12) and G12V
(gly12→ val12), representing 58% and 29% of mutations
respectively (Table 1). No mutations in codon 61 were
found in any of the tumours. All 28 successfully analysed
benign-appearing fallopian tubes were KRAS wild-type.
Notably, 13 (46.4%) of these fallopian tube samples wereTable 1 Distribution of specific KRAS mutations in 17
cases
Mutation Amino acid N % %
GGT→ GAT gly12→ asp12 5 29
GGT→ TGT gly12→ cys12 1 6
GGT→ GTT Gly12→ val12 5 29
GGT→ GCT gly12→ alanin12 2 12
GGT→ AGT gly12→ ser12 2 12
GGT→ CGT gly12→ arg12 1 6
GGT→ GAC gly13→ asp13 1 6
Total 17 100derived from patients diagnosed with serous carcinoma,
all of which were also being KRAS wild-type (Table 2).
Only 2/3 mucinous tumours with concomitantly sampled
fallopian tubes harboured KRAS mutations (Table 2).
Haematoxylin and eosin stained images from one case of
endometroid carcinoma with concurrent ovarian endo-
metriosis, and a pyrogram trace demonstrating a G12D
(GGT→GAT) mutation in base 2 of codon 12, is shown
in Figure 1.
Associations of KRAS mutation status with
clinicopathological and molecular parameters
Associations of KRAS mutation status with established clin-
icopathological and molecular characteristica are shown in
Table 3. KRAS mutation was significantly associated
with lower grade (p = 0.001), mucinous histological sub-
type (p = <0.001) and with PR expression (p = 0. 035),
and a borderline significant inverse association with ex-
pression of Chek1 (p = 0.053). No associations were
found between KRAS mutation status and age, clinical
stage, or expression of ER, AR, or Chek2. Moreover,
there were no significant associations between KRAS
mutation status and expression of the proteins MCM3,
RBM3, Ki67 or SATB1 (data not shown).
Impact of KRAS mutation status on survival from EOC
Kaplan-Meier analysis of the entire cohort (n = 153) re-
vealed a significantly improved OCSS for patients with a
KRAS mutation compared to KRAS wild-type patients
(p = 0.015, Figure 2A). These associations were con-
firmed in univariable Cox regession analysis (HR = 2.51;
95% CI 1.17-5.42) but did not remain significant in mul-
tivariable analysis, adjusted for age, differentiation grade
and clinical stage (HR = 1.46; 95% CI 0.61-5.42). Strati-
fied analysis according to grade (well-moderate vs poorly
differentiated) and stage (Figo I-II vs III-IV) revealed
that the beneficial prognostic impact of KRAS mutation
was only evident in tumours of low and intermediate dif-
ferentiation grade (p = 0.023, Figure 2B) and tumours in
a less advanced (FIGO I-II) clinical stage (p = 0.014,
Figure 2D).
Next, we examined whether the prognostic value of
KRAS mutation status may differ according to histological
subtype (Figure 3). This revealed that KRAS mutation was
associated with a significantly improved OCSS in endo-
metroid carcinomas (p = 0.012, Figure 3C), while KRAS
mutation status was not a prognostic factor in mucinous
(Figure 3A) or serous carcinomas (Figure 3B).
KRAS mutation status did not remain an independent
prognostic factor in the subgroup analyses according to
grade, stage and histological subtype, and there were no
significant associations of KRAS mutation status with
survival by grade and stage within different histological
subtypes (data not shown). Overall survival rates were




Number of sampled fallopian tubes according to histological subtype
TotalMucinuos Serous Endometroid Clear cell Undifferentiated
Wild-type 1 13 9 1 2 26
G12V 1 1
G12S 1 1
Total 3 13 9 1 2 28
Nodin et al. Diagnostic Pathology 2013, 8:106 Page 4 of 9
http://www.diagnosticpathology.org/content/8/1/106also compared in different subgroups and showed results
in concordance with OCSS, (data not shown).
Discussion
Epithelial ovarian cancer is a highly heterogenous dis-
ease with divergent clinical behaviour. This heterogen-
eity is not only reflected in the occurrence of different
histological subtypes, but also in the tumourigenetic
pathways [8,10,14,23-25]. While KRAS mutations have
been demonstrated to signify Type 1 tumours, and
hence, generally associated with a more favourable clin-
ical course [10,13,26,27], few studies have investigated
the prognostic value of KRAS mutation status in EOC.
In this study, we have examined the occurrence, clinico-
pathological correlates and prognostic significance of
KRAS mutation status in invasive tumours from 153
incident EOC cases from two prospective, population-
based Swedish cohorts. The results demonstrate a fre-
quency of KRAS mutations in line with previous reportsFigure 1 KRAS-mutated endometroid cancer with concurrent endome
endometroid carcinoma with (B) concurrent endometriosis in the ovary an
codon 12.[23,28,29]. All but one of the 17 (11%) cases with a
KRAS mutation had mutations in codon 12, and one in
codon 13. In resemblance with other studies [28,30] the
most common amino acid substitutions in codon 12
were G12D (gly12→ asp12) and G12V (gly12→ val12).
None of the cases harboured a mutation in codon 61,
which is well in line with previous reports [10,11,28,31].
KRAS mutation status was also analysed in samples
from benign-appearing fallopian tubes from 28 patients.
All fallopian tube samples were KRAS wild-type, and
KRAS mutations were only seen in two of three corre-
sponding mucinous tumours. Although these findings
do not allow any further conclusions regarding the puta-
tive origin of different EOC types, it would be of interest
to analyse the occurrence of KRAS mutations in a larger
set of matched fallopian tubes and invasive serous carcin-
omas, since the majority of these seem to derived from
tubal epithelium [14]. Moreover, as this carcinogenetic
pathway may proceed via the precursor lesion designatedtriosis. Haematoxylin and eosin stained sections of (A) an
d (C) a pyrogram showing a G12D (gly12→ asp12) mutation in
Table 3 Associations of KRAS mutation status with
clinicopathological and molecular characteristics in 153
patients
n (%) KRAS wild type KRAS mutated P-value
136(89%) 17(11%)
Age









Well-moderate 36(26.5%) 11(64.7) 0.001
Poor 100(73.5) 6(35.3)
Clinical Stage






















Low 43(33.6) 9(56.2) 0.075
High 85(66.4) 7(43.8)
Missing 8 1
Nodin et al. Diagnostic Pathology 2013, 8:106 Page 5 of 9
http://www.diagnosticpathology.org/content/8/1/106“serous intraepithelial tubal carcinoma (STIC) it would
also be of interest to analyse the occurrence of specific
mutations in this entity [32].The significant association between KRAS mutation
and mucinous histological subtype found here is well in
line with previous reports [10,11,26,33].
The results from our study demonstrate that KRAS
mutation is overall significantly associated with an im-
proved survival in unadjusted analysis, but not in a mul-
tivariable model including age, differentiation grade and
clinical stage, which is most likely explained by its asso-
ciation with a less aggressive tumour phenotype [14,34].
In line with previous findings, we found a strong associ-
ation between KRAS mutations and more well-
differentiated tumours [23,27]. Notably, all tumours in
this study have been graded as well-, moderate- and
poorly differentiated, according to the traditional three-
tiered system. Recently, a two-tiered grading system into
low-grade and high-grade tumours has been proposed
for serous carcinomas, which seems to give more accur-
ate prognostic and treatment predictive information for
this category of tumours [35]. Since the overall propor-
tion of tumours classified as being well-differentiated
was rather low in this cohort, 8/154 (5.5%) in the full co-
hort and 2/90 (2.2%) among serous carcinomas, a
dichotomized variable of well-moderately vs poorly dif-
ferentiated grade was applied in the analyses. Neverthe-
less, although the two-tiered grading system may indeed
be more informative about the nature and clinical be-
haviour of serous carcinomas, subgroup analysis did not
reveal a differential prognostic impact of KRAS mutation
status according to differentiation grade in serous car-
cinomas in our study.
We found no significant association between KRAS mu-
tation status and clinical stage in this study, although the
proportion of patients with FIGO Stage III-IV disease was
higher in KRAS wild-type patients compared to KRAS
mutated patients. Survival analysis stratified by clinical
stage revealed that KRAS-mutation was associated with a
favourable prognosis in tumours being in a less advanced,
FIGO I-II, clinical stage, but not in FIGO Stage III-IV tu-
mours, irrespective of histological subtype.
Of note, the fact that KRAS mutation status was only
prognostic in more well-differentiated and less clinically
advanced tumours may well be explained by the more
frequent occurrence of KRAS mutations in these tu-
mours, and should therefore be confirmed in larger co-
horts before any further conclusions can be drawn.
Although being based on post-hoc analysis in a rather
small subgroup, the finding of a significant prognostic
value of KRAS mutation status in endometroid carcin-
omas is of potential interest, and has, to the best of our
knowledge, not been demonstrated before. Of note,
KRAS mutations have been suggested to distinguish
endometroid carcinomas that are related to endometri-
osis from those that are not related to endometriosis
[36] further indicating that KRAS status may indeed
Figure 2 Kaplan-Meier estimates of the prognostic impact of KRAS mutation status on survival from ovarian cancer in the full cohort
and according to differentiation grade and clinical stage. Kaplan-Meier analysis of ovarian cancer specific survival according to KRAS
mutation status (A) in the full cohort, (B) in tumours of high-intermediate and (C) poor differentlation grade, in (D) FIGO Stage I-II tumours and
(E) FIGO Stage III-IV tumours.
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endometroid carcinoma. Again, these findings need to
be confirmed in a larger cohort of endometroid carcin-
omas, wherein the mutational status of concomitant
endometriotic lesions should also be analysed. In this
study, KRAS mutation status was not a prognostic fac-
tor in serous carcinomas, but, notably, the vast major-
ity of tumours in this histological subgroup were
KRAS wild-type.
A limitation to the present study is the lack of infor-
mation on residual tumour after surgery, which is an
important prognostic factor in EOC [37]. However, asKRAS mutation status did not provide any independent
prognostic value, inclusion of this information in the
multivariable model is not likely to have altered our
findings.
In this study, we examined the associations between
KRAS mutation status and several investigative fac-
tors, e.g. expression of hormone receptors AR, ER, PR,
whereby an positive association was found between
KRAS mutation and PR, but not ER or AR expression.
High AR expression has previously been found to be
an independent favourable prognostic factor in serous
ovarian carcinoma in the here studied cohort, while
Figure 3 Kaplan-Meier estimates of the prognostic impact of
KRAS mutation according to histological subtype. Kaplan-Meier
analysis of ovarian cancer specific survival according to KRAS mutation
status in (A) mucinous, (B) serous and (C) endometrial tumours.
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the full cohort nor in subgroup analysis according to
histological type [17]. The inverse association between
KRAS mutation and PR expression found here is in
line with previous studies demonstrating a higher ex-
pression of ER and PR in low-grade serous carcinomas
[38,39], although the number of KRAS-mutated serous
tumours in our study was too low to make any direct
comparisons [40]. Moreover, in another study, Hogdall
et al. found that elevated expression of ER and PR,
alone or in combination, was associated with an im-
proved survival in a cohort of 773 Danish EOC pa-
tients [41].
Of note, KRAS mutational status was not signifi-
cantly associated with expression of SATB1, a global
gene regulator that has been demonstrated to be an
independent factor of poor prognosis in high-grade
tumours in the here examined cohort [21], as well as
in several other cancer forms, e.g. breast [42] and
colorectal cancer [43,44].
The borderline significant inverse association of
KRAS mutation and high expression of Chek1 is well in
line with the association of KRAS wild-type tumours
being more genetically unstable [45]. DNA hyper-
replication as a consequence of hyperproliferative
oncogenic stimuli exposes the cell to replication
stress [46] and triggers the activation of the check-
point response [47,48]. Tumour cells often aquire
defects in the checkpoint response in an early stage
of tumour formation and deactivation of checkpoint
proteins has been reported to cause genomic in-
stability and predisposition to transformation into
neoplastic cells [47-49].Conclusions
In this pooled prospective cohort of epithelial ovarian
cancer, significant associations were found between
KRAS mutations and mucinous histology, well differen-
tiated tumours and positive progesterone expression.
Patients with KRAS mutated tumours had a signifi-
cantly improved survival in unadjusted analysis, and
this beneficial impact of KRAS mutations on survival
was only evident in patients having well and moderately
differentiated tumours, and patients being diagnosed in
a less advanced clinical stage. A finding of potential
interest is the significant prognostic impact of KRAS
mutation in endometroid carcinomas, but not in other
histological subtypes. This association should be vali-
dated in future studies comprising larger patient co-
horts, as the value of KRAS mutation status as a
predictor of response to therapies targeting the Ras/
Raf/MEK/ERK-pathway may differ by histological
subtype.
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